EMA Management Board Meets to Discuss New Location
The agency met to discuss its new temporary and permanent premises in Amsterdam.
On Feb. 1, 2018, the Management Board of the European Medicines Agency met to discuss the agency’s future locations in Amsterdam. EMA will move from London to Amsterdam by the end of March 2019 and will move into a temporary residence until its new permanent location can be built.
The permanent location will be a new, tailor-made facility in the business district of Zuidas in Amsterdam. Details on the new, permanent location were given to the agency by the Dutch government. Because the building will not be complete by March 30, 2019, when EMA must relocate, a temporary location must be prepared. The agency stated in a press release that the temporary building, located in the Sloterdijk area, will be refurbished by January 1, 2019
The agency also discussed the dossier that will be submitted to the Budgetary Authority. EMA must gain a positive opinion from the Budgetary Authority before it can enter into a contractual obligation. EMA will gradually relocate staff to Amsterdam by the end of March 2019.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
